Literature DB >> 23820635

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Jens Juul Holst1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23820635     DOI： 10.1007/s00125-013-2984-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  37 in total

1.  Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2013-06-07

Review 2.  Glucagon antagonism as a potential therapeutic target in type 2 diabetes.

Authors:  J I Bagger; F K Knop; J J Holst; T Vilsbøll
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

3.  GLP-1 does not not acutely affect insulin sensitivity in healthy man.

Authors:  L Orskov; J J Holst; J Møller; C Orskov; N Møller; K G Alberti; O Schmitz
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

4.  Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas.

Authors:  J de Heer; C Rasmussen; D H Coy; J J Holst
Journal:  Diabetologia       Date:  2008-09-16       Impact factor: 10.122

5.  Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.

Authors:  K Moens; H Heimberg; D Flamez; P Huypens; E Quartier; Z Ling; D Pipeleers; S Gremlich; B Thorens; F Schuit
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

6.  Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

Authors:  A Hvidberg; M T Nielsen; J Hilsted; C Orskov; J J Holst
Journal:  Metabolism       Date:  1994-01       Impact factor: 8.694

7.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Authors:  J Eng; W A Kleinman; L Singh; G Singh; J P Raufman
Journal:  J Biol Chem       Date:  1992-04-15       Impact factor: 5.157

8.  Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.

Authors:  Christine Longuet; Ana M Robledo; E Danielle Dean; Chunhua Dai; Safina Ali; Ian McGuinness; Vincent de Chavez; Patricia M Vuguin; Maureen J Charron; Alvin C Powers; Daniel J Drucker
Journal:  Diabetes       Date:  2012-11-16       Impact factor: 9.461

9.  Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Authors:  Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler
Journal:  Diabetes       Date:  2012-01-20       Impact factor: 9.461

10.  The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

Authors:  Niels C B Nyborg; Anne-Marie Mølck; Lars W Madsen; Lotte Bjerre Knudsen
Journal:  Diabetes       Date:  2012-02-14       Impact factor: 9.461
View more
  2 in total

1.  Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

Authors:  S Bonner-Weir; P A In't Veld; G C Weir
Journal:  Diabetes Obes Metab       Date:  2014-01-29       Impact factor: 6.577

2.  Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!

Authors:  Michael A Nauck; Juris J Meier
Journal:  J Diabetes Sci Technol       Date:  2014-05-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.